Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 260,529 shares of the conglomerate’s stock, valued at approximately $187,591,000.
Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Danaher during the second quarter worth approximately $10,492,520,000. State Street Corp boosted its holdings in shares of Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the period. Capital International Investors boosted its holdings in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after purchasing an additional 1,334,221 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Danaher by 11.2% in the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after purchasing an additional 1,517,904 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have weighed in on DHR. Wells Fargo & Company decreased their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. DZ Bank began coverage on Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price target on the stock. TD Cowen cut their price target on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, Citigroup started coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $228.91.
Danaher Stock Up 0.3%
Danaher stock opened at $219.42 on Monday. The business has a fifty day moving average of $195.80 and a two-hundred day moving average of $192.40. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market cap of $154.25 billion, a P/E ratio of 38.97, a P/E/G ratio of 2.72 and a beta of 0.78. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $0.77 EPS. On average, analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Read More
- Five stocks we like better than Danaher
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
